Apogen Biotechnologies, a US-based oncological therapy spinout of University of Minnesota, boosted its series A round to $11m yesterday with a $4m extension from investors including pharmaceutical firm Merck Group.
Merck contributed to the capital through its corporate venturing subsidiary M Ventures, and was joined by unnamed, existing investors.
Apogen previously raised an initial $7m tranche in 2016 from WRF Capital, the investment arm of commercialisation firm Washington Research Foundation, Arch Venture Partners and Accelerator Life Science…